Plus Therapeutics (Plus Therapeutics) Cash And Cash Equivalents : $8.55 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Cash And Cash Equivalents?

Plus Therapeutics's quarterly cash and cash equivalents increased from Jun. 2023 ($10.90 Mil) to Sep. 2023 ($11.01 Mil) but then stayed the same from Sep. 2023 ($11.01 Mil) to Dec. 2023 ($8.55 Mil).

Plus Therapeutics's annual cash and cash equivalents declined from Dec. 2021 ($18.40 Mil) to Dec. 2022 ($18.12 Mil) and declined from Dec. 2022 ($18.12 Mil) to Dec. 2023 ($8.55 Mil).

Plus Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Plus Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Cash And Cash Equivalents Chart

Plus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

17.55

8.35

18.40

18.12

8.55

Plus Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															18.12	12.72	10.90	11.01	8.55

Plus Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Plus Therapeutics (NAS:PSTV) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Plus Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Plus Therapeutics (Plus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

XMP0:Germany

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.plustherapeutics.com

Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.

Executives

Marc H Hedrick	officer: President	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk	director	LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes	director	217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen	director	3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre	officer: Chief Financial Officer	4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance	officer: CHIEF MEDICAL OFFICER	MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van	director	6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance	10 percent owner	MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote	10 percent owner	CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell	director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino	officer: Chief Medical Officer	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris	officer: VP and GM of Cell Therapy	3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton	director	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey	director